ProfileGDS5678 / 1439759_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 74% 74% 71% 74% 78% 79% 75% 74% 73% 74% 73% 76% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1194376
GSM967853U87-EV human glioblastoma xenograft - Control 24.8758174
GSM967854U87-EV human glioblastoma xenograft - Control 34.8719974
GSM967855U87-EV human glioblastoma xenograft - Control 44.6210271
GSM967856U87-EV human glioblastoma xenograft - Control 54.8166474
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1842378
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3214179
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9522975
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.788174
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7101973
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8894174
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7179373
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1014176
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9077775